We’re a different kind of biotech company.
And we’re here to make a difference
At Prometheus Biosciences, we aim to transform the paradigm of patient care with a proprietary precision-based approach to IBD and autoimmune diseases. By harnessing the power of machine learning and leveraging the world’s most comprehensive collection of IBD patient data.
We’re not just changing the game. We’re changing lives. With the promise of targeted treatments.
The story of Prometheus Biosciences
It all started more than 20 years ago at Cedars-Sinai Medical Center where one of our founders, IBD luminary Dr. Stephan Targan, began building the IBD biobank. He recognized the potential of pairing IBD patient bio-samples with longitudinal clinical data—and this research led to the discovery of TL1A, the target of our lead program.
Dr. Stephan Targan
Dr. Dermot McGovern
Dr. Janine Bilsborough
The IBD biobank continued to evolve under the guidance of Dr. Dermot McGovern, who provided key genetics and computational expertise. Dr. Janine Bilsborough brought biotech and industry expertise, and spearheaded enhanced approaches to translating the learnings gleaned from the biobank into novel therapeutic strategies.
In 2016, with significant investment and the support of Cedars-Sinai’s Technology Transfer Office led by Jim Laur, the founders partnered with serial entrepreneur Scott Glenn to form a new company. The goal: to capitalize on their vision, the first precision medicine approach to IBD. Initially named Precision IBD, the company later became Prometheus Biosciences.
Cedars-Sinai and their exceptional IBD team remain close partners and collaborators, as we continue to develop new medicines for IBD and beyond.